SAFETY PROBLEMS OF DRUG USE DURING PREGNANCY AND BREASTFEEDING


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The effects of drugs on the course of pregnancy remain little studied and the opinions about the safety of their use are ambiguous. To study drug safety during pregnancy is presently considered to be a priority of pharmacoviligance in the USA and European Union. In Russia, health care facilities and pharmaceutical companies may enter reports on the negative effect of drugs on the course and outcome of pregnancy just into the pharmacoviligance database at the Roszdravnadzor website and physicians may send them to the regional or federal drug safety monitoring center. Along with pregnancy drug safety testing during the physicians’ level of knowledge in this area should be increased.

关键词

全文:

受限制的访问

作者简介

E. USHKALOVA

Russian Peoples' Friendship University; Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: eushk@yandex.ru

O. TKACHEVA

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

N. CHUKHAREVA

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

参考

  1. Оганов Р.Г., Ткачева О.Н. и др. Лечебно-диагностическая тактика ведения беременных с артериальной гипертонией в России: диагностика и классификация (результаты многоцентрового эпидемиологического исследования ДИАЛОГ II) // Акуш. и гин. — 2010. — № 5. — C. 42—48.
  2. Стриженок Е.А., Гудков И.В., Страчунский Л.С. Применение лекарственных средств при беременности: результаты многоцентрового фармакоэпидемиологического исследования // КМАХ. — 2007. — Т. 9, № 2. — С. 162-175.
  3. Brent R.L., Beckman D.A. The contribution of environmental teratogens to embryonic and fetal loss // Clin. Obstet. Gynecol. — 1994. - Vol. 37. — Р. 646 — 670.
  4. EMEA 2010 priorities for drug safety research. Medicine use in pregnancy. http://www.emea.europa.eu/pdfs/human/phv/49372409en.pdf.
  5. FDA. Health organizations to study safety of medications taken during pregnancy. For immediate release: Dec. 30, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm195934.htm
  6. Geib L.T., Vargas Filho E.F., Geib D. et al. Prevalence and determinants of medication during pregnancy by risk class among mothers of liveborn infants // Cad. Saude Publ. — 2007. — Vol. 23, № 10. — Р. 2351—2362.
  7. Gwee M. C. Can tetracycline-induced fatty liver in pregnancy be attributed to choline deficiency? // Med. Hypothes. — 1982. — Vol. 9, № 2. — Р. 157—162.
  8. Hamel B.C. Syndromes 8. The diagnosis of congenital anomalies and syndromes // Ned T. Tandheelkd. — 1999. — Vol. 106, № 2. — Р. 51—53.
  9. Lo W.Y., Friedman J.M. Teratogenicity of recently introduced medications in human pregnancy // Obstet. and Gynecol. — 2002. — Vol. 100. — P. 465-473.
  10. McCormack W.M., George H., Donner A. et al. Hepatotoxicity of erythromycin estoate during pregnancy // Antimicrob. Agents Chemother. — 1997. — Vol. 12. — P. 630—635.
  11. Nahum G.G. et al. Antibiotic use in pregnancy and lactation. What is and is not known about teratogenic and toxic risks // Obstet. and Gynecol. — 2006. — Vol. 107. — P. 1120— 1138.
  12. Sit D.K., Perel J.M., Helsel J.C., Wisner K.L. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum // J. Clin. Psychiatry. - 2008. — Vol. 69, № 4. — P. 652—658.
  13. Tomson T., Lindbom U., Ekqvist B., Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin // Epilepsia. — 1994. — Vol. 35. — P. 122—130.
  14. Ventura S.J., Martin J. A., Curtin S. C. et al. Births: Final Data for 1998 // National Vital Stat. Rep. — 2000. — Vol. 48, № 3. — P. 1-100.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011
##common.cookie##